阿尔茨海默病的唾液生物标志物:通过元分析进行系统审查
Kacper Nijakowski1, Wojciech Owecki2, Jakub Jankowski2
1Department of Conservative Dentistry and Endodontics, Poznan University of Medical Sciences, 60-812 Poznan, Poland.
International journal of molecular sciences
|January 23, 2024
概括
唾液生物标志物显示出对诊断阿尔茨海默病 (AD) 的前景. 在阿尔茨海默病患者中观察到升高的β-粉样蛋白42和p-tau,与降低的t-tau和乳酸,支持早期诊断.
科学领域:
- 神经退行性疾病的神经退行性疾病
- 发现生物标志物的发现.
- 诊断工具 诊断工具 诊断工具
背景情况:
- 阿尔茨海默病 (AD) 是导致痴呆的主要原因,其特点是认知能力下降.
- 目前的诊断方法可能具有侵入性和成本.
- 唾液为生物标志物收集提供了一个非侵入性的替代方案.
研究的目的:
- 系统地审查唾液生物标志物的可靠性,以诊断阿尔茨海默病.
- 评估特定的唾液分析物,包括蛋白质,代谢物和miRNAs.
主要方法:
- 按照PRISMA指南进行系统审查.
- 包括30项相关研究.
- 唾液生物标志物水平和诊断精度 (AUC) 的元分析.
主要成果:
- 在AD患者中,唾液β-胺42和p-tau水平显著增加.
- 唾液中的t-tau和乳酸水平显示出边界显著性下降.
- 通过聚合的AUC,乳二和β-粉胺42显示了对AD诊断的显著预测价值.
结论:
- 在阿尔茨海默氏症患者中可以检测到唾液β-粉样蛋白42,和乳酸.
- 这些唾液生物标志物显示出对AD的可靠,早期诊断的潜力.
- 进一步验证可能会将唾液确定为神经退行性疾病的关键诊断液.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的疾病.贝塔氨基化物-贝塔氨基化物生物标志物 生物标志物乳酸铁氨酸 (lactoferrin) 是一种乳酸铁氨酸.神经退行性疾病的神经退行性疾病这是唾液,唾液.知道的 知道的 知道的更多相关视频
07:08A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
7.8K
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
865
相关概念视频
01:26Alzheimer's Disease: Overview
490
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
490
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195